JPRN-jRCT2080224978已完成2 期
Phase II/III clinical trial of L-105 in pediatric patients with hepatic encephalopathy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 <= 17age old（—）
- 性别
- All
入选标准
- •Patients should be eligible for the study if they meet all the following criteria:
- •1) Japanese pediatric patients aged under 18 when a consent form is obtained
- •2) Hyperammonemia (over 66 ug/dL of blood ammonia level) at enrollment
- •3) Grade I or II mental state of H.E. (Classification by criteria for pediatric HE or Inuyama Symposium) at enrollment
- •4) Patient who has any of the following basic diseases.
- •Hepatic cirrhosis, biliary atresia, portal hypertension (including Bunch syndrome), congenital absence of the portal vein (including portal-systemic shunt), Wilson disease, urea cycle disorder (chronic phase) and lysinuric protein intolerance
- •5) Obtained a consent from the legal representative (parents or legal gurdian) after sufficient study information is given to them. In addition, explain the study information as much as possible to the subject, when the principal investigator or coinvestigator concludes that the patient have ability to provide assent, the informed assent would be obtain from the pediatric subject.
排除标准
- •Patients should be ineligible for the study if the patient meets either one of the following criteria
- •1) A concurrent disease or medical history (such as mental illness, metabolic disorders except Wilson disease, urea cycle disorder and lysinuric protein intolerance, chronic renal failure, hypertension, diabetes mellitus, hypoglycemia, myocardial infarction, cardiac failure, cerebral infarction, cerebro-degenerative disease, malignant tumor and Mycobacterium tuberculosis infection) of the patient is concluded by the principal investigator or coinvestigator that this may impact the study assessment.
- •2) Acute hepatitis or in the acute exacerbation phase of chronic hepatitis
- •3) Patients having either one of the following concurrent diseases
- •Ascites requiring regular drainage
- •Bleeding due to rupture of esophageal or gastric varicoses
- •Spontaneous bacterial peritonitis
- •Severe electrolyte abnormality that may impact the psychoneurological function
- •4) Laboratory values meet either one of the following levels at enrollment
- •BUN over 25 mg/dL and serum creatinine over 2.0 mg/dL
- •hemoglobin under 7 g/dL
- •serum potassium under 2.5 mEq/L
- •5) Patients using an antibacterial agent (excluding a dermatological agent) either one of the following periods
- •Within 6 days prior to the examinations of Blood ammonia level, Mental state, and Number connection test-A and test-B
- •Within 1 week prior to the study medication
- •6) Unable to discontinue a drug prohibited for concomitant use in the study
- •7) Patients who proved impossible to administer the investigational drug for 2 weeks or more
- •8) Previous history of allergy to rifamycin antibiotics
- •9) Having received other investigational drugs within 16 weeks prior to the study medication
- •10) Patients who have difficulty taking tablets (10.2 mm in diameter)
- •11) Person in reproductive age and also are pregnant (possibly pregnant) or lactating or willing to become pregnant (including those who are unable to have appropriate contraception)
- •12) Other patients whom the principal investigator or coinvestigator concludes ineligible for the study
研究者
相似试验
未知
2 期
Phase II/III clinical trial of L-105 in patients with hepatic encephalopathyH.E.JPRN-jRCT2080222040ASKA Pharmaceutical Co., Ltd.180
未知
3 期
Phase III clinical trial of L-105 in patients with hepatic encephalopathyH.E.JPRN-jRCT2080222041ASKA Pharmaceutical Co., Ltd.180
已完成
3 期
A clinical trial of MLD-55 in pediatric patients with depressioJPRN-jRCT2080224520Mochida Pharmaceutical Co., Ltd.72
进行中（未招募）
1 期
A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathwayEUCTR2010-019348-37-FRovartis Pharma Services AG24
进行中（未招募）
不适用
A phase 1 study of LDE225 in pediatric patients with refractory or recurrent medulloblastoma or other tumors potentially dependent on the Hedgehog signaling pathway - NDPatients (aged = 12 months and < 18 years) with recurrent or refractory MB, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade glioma, or osteosarcoma that has progressed despite treatment with standard therapies, or for which no standard treatments are available.MedDRA version: 13.1Level: PTClassification code 10008126Term: Cerebral neuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10061750Term: Cerebellar tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019348-37-ITOVARTIS FARMA24